NCT02766634View on ClinicalTrials.gov

A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen)

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

March 31, 2016

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
Neutropenia (Low White Blood Cell Count)
Interventions
BIOLOGICAL

Filgrastim Hospira (US)

5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days

BIOLOGICAL

U.S.-approved Neupogen®

5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days

Trial Locations (2)

33126

SeaView Research, Inc., Miami

33134

SeaView Research, Inc., Miami

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
collaborator

Hospira, now a wholly owned subsidiary of Pfizer

INDUSTRY

lead

Pfizer

INDUSTRY

NCT02766634 - A Research Study To Test How Multiple Doses Of Filgrastim Hospira Works In The Body Of Healthy Study Subjects When Given by Subcutaneous Injection (SC) (Shot) Compared To An Already U.S.-Approved Drug Neupogen® (Amgen) | Biotech Hunter | Biotech Hunter